INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.9600
+0.1800 (+3.77%)
At close: 4:00PM EST

5.00 +0.04 (0.81%)
After hours: 6:41PM EST

Stock chart is not supported by your current browser
Previous Close4.7800
Open4.8900
Bid4.93 x 3200
Ask5.00 x 2200
Day's Range4.7300 - 4.9750
52 Week Range3.3500 - 11.6500
Volume1,081,723
Avg. Volume800,491
Market Cap368.378M
Beta (3Y Monthly)2.39
PE Ratio (TTM)N/A
EPS (TTM)-1.71
Earnings DateMar 6, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Trade prices are not sourced from all markets
  • Opioid maker used rap video to push powerful painkiller
    Associated Press5 hours ago

    Opioid maker used rap video to push powerful painkiller

    BOSTON (AP) — Employees at a drug company accused of bribing doctors rapped and danced around a person dressed as a bottle of the highly addictive fentanyl spray in a video meant to motivate sales reps to push the drug.

  • Worst Performing Cannabis Stocks in 2018
    Investopedia11 hours ago

    Worst Performing Cannabis Stocks in 2018

    In spite of a notable year for the marijuana industry, some stocks failed to meet performance expectations.

  • ACCESSWIRE7 days ago

    4 Marijuana Stocks Looking To Pick Up Speed This Month

    CORAL GABLES, FL / ACCESSWIRE / February 8, 2019 / Marijuana stocks have become one of the hottest topics in the news over the course of the past few years. Recently, the cannabis industry has seen an increase in capital enjoyed by companies working to optimize and innovate products for the adult-use recreational cannabis market. As it relates to positive legislation brought forth by lawmakers, as many as 33 states in the U.S. have passed laws allowing for the use of cannabis, with many of those offering recreational cannabis as well.

  • InvestorPlace8 days ago

    Zynerba Stock Is Marijuana-Adjacent Play Worth a Look

    Lately, the pharmaceutical companies are trying to use cannabis-based therapies to treat all sorts of medical conditions. Zynerba (NASDAQ:ZYNE) is another contender in this increasingly-crowded field. Whether that's a good or bad thing for Zynerba stock remains to be seen.After all, they appear to have a pretty interesting play within the space. Their ZYN002 drug candidate is, according to the company, "the first and only pharmaceutically-produced CBD formulated as a permeation‑enhanced gel for transdermal delivery".They are running studies on this CBD gel for a variety of conditions. They are investigating treatments for Fragile X, Tourette's, and seizures, among other conditions.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Monster Growth Stocks to Buy for 2019 and Beyond Understanding The Fragile X Syndrome Therapeutic LandscapeFragile X Syndrome is a relatively rare condition occurring in roughly 1 out of every 4,000 boys and 1 out of every 8,000 girls. Researchers believe that the condition is caused by a DNA defect. Fragile X often presents symptoms in children by age 2 including intellectual disability and physical characteristics such as long face and a prominent jaw.It is sometimes a complicated diagnosis as Fragile X can look like other developmental disorders. Many Fragile X children have Attention Deficit Disorder. Additionally, many exhibit features of autism disorders. Furthermore, a significant number of Fragile X patients have frequent seizures.This leads to an interesting position for Zynerba. The company states that there are no approved drug therapies for Fragile X. However, it notes that doctors use various drugs off-label to treat various Fragile X symptoms. That makes sense, as there are treatments for things such as seizures.Directly, as far as competition, Zynerba notes that Neuren Pharmaceuticals, Ovid Therapeutics (NASDAQ:OVID) and Marinus Pharmaceuticals (NASDAQ:MRNS) are all active in the research space seeking a treatment directly for Fragile X syndrome.That's not all. Zynerba has focused on the treatment of seizures in particular. Within that particular space, it faces cannabinoid-based competition on several fronts. GW Pharma (NASDAQ:GWPH), with its more than $4 billion market cap, is targeting this space and is widely thought of as a leader in cannabinoid research.Additionally, Insys (NASDAQ:INSY) is researching CBDs for seizures and infantile spasms as well. So, should Zynerba's ZYN002 be a clinical success, it won't necessarily be the first or best therapy that reaches the market. Why Zynerba Stock Popped RecentlyOn January 28th, Zynerba stock shot up 30% to reach $4.80. In subsequent days, it rallied further, reaching as high as the $6 mark. What happened on Jan. 28 that set the rally in motion? There doesn't appear to be much in the way of hard news, but the company did give a high-profile presentation and it appears this set investor enthusiasm in motion.In this presentation, the company confirmed that things are moving along as planned for its combination Phase 2/3 CONNECT trail for Fragile X syndrome. Zynerba also expects to release results for its Phase 2 trial for developmental and epileptic encephalopathies in the latter half of 2019.To add to that, Zynerba remains in reasonably strong financial position. The company reported $59.8 million in cash as of December 31st, 2018.Given its current burn rate, that should give Zynerba funds to continue its current research through the second half of 2020. While Zynerba will have to raise more funds at some point, it still has plenty of time to deliver its crucial trial results later in 2019 before going back to the market for more money. The CBD FactorIt's difficult to consider ZYNE stock without thinking about the X factor here: investor enthusiasm for marijuana-related stocks. Since late December the Alternative Harvest (NYSEARCA:MJ) marijuana ETF has ripped 50% higher off the lows. Stocks like Aphria (NYSE:APHA) and Canopy Growth (NYSE:CGC) are soaring almost every day.Zynerba itself hadn't participated in this enthusiasm, at least not until recently. However, that may be changing. Recently, famous TV host Jim Cramer talked up so-called "marijuana-adjacent" biotech firms as stocks with big potential in 2019.Cramer said:"These are not pot companies. They are drug companies focused on developing artificial cannabinoids that mimic what cannabis does to your body […] As we get more and more data showing the efficacy of medicinal marijuana, I think more investors will embrace actual medicines that do the same thing as marijuana, but they do it more reliably."With ZYNE stock, you are getting a call option on this thesis playing out later in 2019. Zynerba Stock VerdictI rarely invest in clinical stage biotech companies. It's a difficult industry; far more companies fail than succeed. Be careful with these sorts of stocks and don't invest more than you can afford to lose.That said, Zynerba has an interesting drug candidate, and is certainly positioned in a hot sector of the market. With plenty of cash to make it into mid-2020, and key data coming before then, ZYNE stock has plenty of speculative value for active traders.One upcoming catalyst to watch out for. On February 11th, CEO Armando Anido will be giving a presentation at the 2019 BIO CEO and Investor Conference. With ZYNE stock remaining volatile in recent days, any further data releases or business updates in this presentation could cause a big move in Zynerba shares.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Are These 7 Dividend Aristocrats ETFs Fit for a King? * 7 of the Best Emerging Markets Stocks to Buy * 5 Gold Stocks That Should Glitter in 2019 Compare Brokers The post Zynerba Stock Is Marijuana-Adjacent Play Worth a Look appeared first on InvestorPlace.

  • ACCESSWIRE8 days ago

    Cannabis Plays Going Higher

    HENDERSON, NV / ACCESSWIRE / February 7, 2019 / January was a historic month for marijuana stocks. Almost all cannabis stocks reported gains last month and the top performers reported gains between 80%-90%. ...

  • ACCESSWIRE10 days ago

    4 Marijuana Stocks Looking to Set the Standard

    As we see what February has in store, Leafbuyer Technologies Inc (OTC:LBUY), MariMed Inc (MRMD), Tilray Inc (TLRY), and INSYS Therapeutics (INSY) are 4 pot stocks worth looking into on Tuesday. Leafbuyer Technologies Inc (OTC:LBUY) is one of the leading online resources for those in the cannabis industry. The Company, through its subsidiary, LB Media Group LLC, operates an online platform for trending cannabis deals and specials and has been lauded as the most comprehensive source for ascertaining cannabis-related information.

  • Top Marijuana Stocks on the NASDAQ
    Investopedia10 days ago

    Top Marijuana Stocks on the NASDAQ

    Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.

  • ACCESSWIRE10 days ago

    Playing the Big Cannabis Rebound

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Cannabis stocks, as measured by the Global Cannabis Stock Index, bounced back from Q4 losses of 44.2%, rallying 44.2% in January, the second-best month in ...

  • The Only 2 Pot Stocks to Fall in January
    Motley Fool10 days ago

    The Only 2 Pot Stocks to Fall in January

    The most widely followed marijuana ETF ended up 48% last month, but 2 cannabis stocks went up in smoke.

  • ACCESSWIRE10 days ago

    Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Some consider the small-cap and mid-cap - ''smid-cap'' - zone with market caps of $5 billion or less, a bit risky. They aren't wrong. However, if you can ...

  • Analyzing CARA, INSY, and GWPH’s Earnings Trends
    Market Realist16 days ago

    Analyzing CARA, INSY, and GWPH’s Earnings Trends

    CARA, INSY, and GWPH: Comparing Medical Cannabis Stocks(Continued from Prior Part)Earnings trends GW Pharmaceuticals’ (GWPH) net income was -$295.2 million in fiscal 2018—compared to -$170.5 million in fiscal 2017. In the first nine months of

  • Cannabis Stocks: CARA, INSY, and GWPH’s Revenue Trajectory
    Market Realist16 days ago

    Cannabis Stocks: CARA, INSY, and GWPH’s Revenue Trajectory

    CARA, INSY, and GWPH: Comparing Medical Cannabis Stocks(Continued from Prior Part)Revenue trendsOn November 27, GW Pharmaceuticals (GWPH) presented its fourth-quarter and fiscal 2018 financial results. GW Pharmaceuticals’ net revenues in fiscal

  • CARA, INSY, and GWPH: Analysts’ Recommendations in January
    Market Realist16 days ago

    CARA, INSY, and GWPH: Analysts’ Recommendations in January

    CARA, INSY, and GWPH: Comparing Medical Cannabis StocksStock performanceOn January 28, Cara Therapeutics’ (CARA) stock price closed at $14.82, which is an ~4.02% discount compared to its previous close and ~14% YTD (year-to-date) growth. The

  • Better Marijuana Stock Buy: Medical Marijuana Inc. vs. Insys Therapeutics
    Motley Fool16 days ago

    Better Marijuana Stock Buy: Medical Marijuana Inc. vs. Insys Therapeutics

    Performance, partnerships, and prospects will determine the smarter play on cannabis right now.

  • ACCESSWIRE16 days ago

    Biotechs You Need to Radar Now

    HENDERSON, NV / ACCESSWIRE / January 30, 2019 / The biotechnology sector has been roaring back strong in 2019. There a few companies that we think you should be researching right now. One company who's ...

  • Insys executive gave doctor lap dance while promoting drug, witness says
    Reuters17 days ago

    Insys executive gave doctor lap dance while promoting drug, witness says

    An ex-stripper who became a regional sales director at Insys Therapeutics Inc gave a doctor a lap dance at a Chicago club as the drugmaker pushed the doctor to prescribe its addictive fentanyl spray, a former Insys employee testified on Tuesday. Former Insys sales representative Holly Brown told jurors the incident with her boss, Sunrise Lee, took place after Insys began rewarding the doctor for prescribing its opioid product by paying him to speak at educational events about the drug.

  • Prosecutor: Drug founder driven by greed in bribing doctors
    Associated Press18 days ago

    Prosecutor: Drug founder driven by greed in bribing doctors

    BOSTON (AP) — The wealthy founder of a drug company plotted to bribe doctors across the country to prescribe a highly addictive fentanyl spray in order to outshine competitors and line his own pockets, a federal prosecutor told jurors Monday.

  • Reuters18 days ago

    'Greed' fuelled Insys founder's opioid bribe scheme - prosecutor

    A lawyer for Insys Therapeutics Inc's one-time billionaire founder on Monday denied that he had any role in the U.S. opioid crisis as a federal prosecutor told jurors he ran a scheme to bribe doctors to prescribe an addictive fentanyl spray. John Kapoor, the drugmaker's former chairman, and four colleagues are the first painkiller manufacturer executives to face trial over conduct authorities say contributed to an opioid abuse crisis that has killed tens of thousands of people a year. Assistant U.S. Attorney David Lazarus told a Boston federal jury at the trial's start that Kapoor oversaw the bribing of doctors who were paid to act as speakers at poorly-attended sham events at restaurants ostensibly meant to educate clinicians about its product, Subsys.

  • Reuters18 days ago

    'Greed' fueled Insys founder's opioid bribe scheme -prosecutor

    A lawyer for Insys Therapeutics Inc's one-time billionaire founder on Monday denied that he had any role in the U.S. opioid crisis as a federal prosecutor told jurors he ran a scheme to bribe doctors to prescribe an addictive fentanyl spray. John Kapoor, the drugmaker's former chairman, and four colleagues are the first painkiller manufacturer executives to face trial over conduct authorities say contributed to an opioid abuse crisis that has killed tens of thousands of people a year. Assistant U.S. Attorney David Lazarus told a Boston federal jury at the trial's start that Kapoor oversaw the bribing of doctors who were paid to act as speakers at poorly-attended sham events at restaurants ostensibly meant to educate clinicians about its product, Subsys.

  • ACCESSWIRE18 days ago

    Biotech Stocks to Watch this Week

    HENDERSON, NV / ACCESSWIRE / January 28, 2019 / Biotech can be a lucrative sector for investors. Companies in the industry are often working toward well-defined goals such as clinical trial results, which ...

  • Reuters19 days ago

    Insys founder, former execs face opioid kickback scheme trial

    The one-time billionaire founder of Insys Therapeutics Inc and four other former executives and managers of the opioid drugmaker will face trial over charges they conspired to pay doctors bribes to prescribe patients an addictive fentanyl spray to boost sales. Lawyers are set to deliver opening statements Monday in federal court in Boston in the case of former Insys chairman John Kapoor, the highest-level executive of a painkiller manufacturer to be tried amid a deadly U.S. opioid abuse epidemic. Prosecutors say Kapoor directed a kickback scheme that helped fuel the epidemic in order to boost the company's sales of Subsys, an under-the-tongue fentanyl spray approved only for use in managing severe pain in cancer patients.

  • Families hoping for justice from prescription bribes trial
    Associated Press21 days ago

    Families hoping for justice from prescription bribes trial

    BOSTON (AP) — Drug company executives weren't satisfied with sales for their powerful painkiller, so they devised a plan, prosecutors say: Offer cash to doctors in exchange for prescriptions. Soon, the highly addictive fentanyl spray was flourishing, and executives were raking in millions.

  • Insys executives used rap video to push sales of potentially lethal opioid
    CBS News Videos2 days ago

    Insys executives used rap video to push sales of potentially lethal opioid

    A newly released video is raising questions about Insys Therapeutics, a company at the center of a criminal investigation stemming from the nation's opioid epidemic. Former executives and managers for Insys are on trial in Boston. They're accused of bribing doctors to prescribe a highly addictive fentanyl spray. Tony Dokoupil reports.

  • Cannabis Company Surges After Winning the ‘POT’ Ticker Lottery
    Yahoo Finance Video14 days ago

    Cannabis Company Surges After Winning the ‘POT’ Ticker Lottery

    Weekend Unlimited, a Cannabis company, wins the POT ticker lottery. Yahoo Finance's Adam Shapiro, Julia La Roche, and Dan Roberts join Weekend Unlimited President & CEO Paul Chu.